Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 4
2005 2
2006 3
2007 1
2008 2
2009 6
2010 6
2011 2
2012 2
2013 7
2014 5
2015 4
2016 6
2017 9
2018 7
2019 6
2020 8
2021 9
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.
Matteo C, Orienti I, Eramo A, Zeuner A, Ferrari M, Passoni A, Bagnati R, Ponzo M, Bello E, Zucchetti M, Frapolli R. Matteo C, et al. Among authors: zucchetti m. Pharmaceutics. 2024 Mar 12;16(3):387. doi: 10.3390/pharmaceutics16030387. Pharmaceutics. 2024. PMID: 38543281 Free PMC article.
Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts.
Demuytere J, Carlier C, Van de Sande L, Hoorens A, De Clercq K, Giordano S, Morosi L, Matteo C, Zucchetti M, Davoli E, Van Dorpe J, Vervaet C, Ceelen W. Demuytere J, et al. Among authors: zucchetti m. Int J Nanomedicine. 2024 Jan 17;19:429-440. doi: 10.2147/IJN.S424045. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38260242 Free PMC article.
Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Ceruti T, Frapolli R, Ghilardi C, Decio A, Dellavedova G, Tommasi S, Zucchetti M, Mangoni AA. Ceruti T, et al. Among authors: zucchetti m. Molecules. 2023 Dec 13;28(24):8056. doi: 10.3390/molecules28248056. Molecules. 2023. PMID: 38138547 Free PMC article.
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V, Valsecchi MG, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Dalla Pozza L, Elitzur S, Silvestri D, Locatelli F, Möricke A, Engstler G, Smisek P, Bodmer N, Barbaric D, Izraeli S, Rizzari C, Boos J, Buldini B, Zucchetti M, von Stackelberg A, Matteo C, Lehrnbecher T, Lanvers-Kaminsky C, Cazzaniga G, Gruhn B, Biondi A, Schrappe M. Conter V, et al. Among authors: zucchetti m. J Clin Oncol. 2024 Mar 10;42(8):915-926. doi: 10.1200/JCO.23.01388. Epub 2023 Dec 14. J Clin Oncol. 2024. PMID: 38096462
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol.
Rizzari C, Möricke A, Valsecchi MG, Conter V, Zimmermann M, Silvestri D, Attarbaschi A, Niggli F, Barbaric D, Stary J, Elitzur S, Cario G, Vinti L, Boos J, Zucchetti M, Lanvers-Kaminsky C, von Stackelberg A, Biondi A, Schrappe M. Rizzari C, et al. Among authors: zucchetti m. Hemasphere. 2023 Jun 1;7(6):e893. doi: 10.1097/HS9.0000000000000893. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37275740 Free PMC article.
Pseudo-resistance to anticancer drugs.
Davoli E, Zucchetti M, Giavazzi R, Garattini S, Frapolli R. Davoli E, et al. Among authors: zucchetti m. Ther Adv Med Oncol. 2022 Nov 14;14:17588359221136776. doi: 10.1177/17588359221136776. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36407785 Free PMC article. No abstract available.
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT).
Stroes CI, Schokker S, Khurshed M, van der Woude SO, Mathôt RA, Slingerland M, de Vos-Geelen J, Zucchetti M, Matteo C, van Dijk E, Ylstra B, Thijssen V, Derks S, Godefa T, Dijksterhuis W, Breimer GE, van Delden OM, Verhoeven RH, Meijer SL, Bijlsma MF, van Laarhoven HW. Stroes CI, et al. Among authors: zucchetti m. Ther Adv Med Oncol. 2022 Jun 28;14:17588359221109196. doi: 10.1177/17588359221109196. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35782751 Free PMC article.
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C, Colombini A, Bettini LR, Porcu L, Barzaghi S, Ceruti T, Silvestri D, Amoroso A, Dell'Acqua F, Gotti G, Nastasi C, Zucchetti M, Rizzari C. Matteo C, et al. Among authors: zucchetti m. Pediatr Blood Cancer. 2022 Sep;69(9):e29753. doi: 10.1002/pbc.29753. Epub 2022 May 13. Pediatr Blood Cancer. 2022. PMID: 35561075
92 results